Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group - Concepedia

Concepedia

Publication | Closed Access

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

390

Citations

21

References

2007

Year

Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard, Binh Bui, Florence Duffaud, Catherine Delbaldo, Antoine Adenis, Patrice Viens, María Rios, Emmanuelle Bompas,

Journal of Clinical Oncology

Abstract

Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity

References

	Year	Citations
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors Seiichi Hirota, Koji Isozaki, Y Moriyama, Science	1998	4.4K
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri, Margaret von Mehren, Charles D. Blanke, New England Journal of Medicine	2002	4.4K
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Journal of Clinical Oncology	2003	2.3K
<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors Michael C. Heinrich, Christopher L. Corless, Anette Duensing, Science	2003	2.3K
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor Heikki Joensuu, Peter Roberts‎, Maarit Sarlomo‐Rikala, New England Journal of Medicine OncologyGastrointestinal OncologyMalignant DiseaseMedicineGrowth Factor Receptor	2001	2.1K
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Allan T. van Oosterom, Ian Judson, Jaap Verweij, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2001	1.3K
Gastric stromal tumors Reappraisal of histogenesis Michael T. Mazur, H. Brent Clark The American Journal of Surgical Pathology	1983	1K
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Brian P. Rubin, Samuel Singer, C. Tsao, PubMed GastroenterologyPathologyCancer BiologyTumor BiologyOncology	2001	968
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors Marcia L. Lux, Brian P. Rubin, Tara L. Biase, American Journal Of Pathology Tumor BiologyGastrointestinal OncologyMedicineKit ExtracellularColorectal Cancer	2000	644

Page 1